TRCT
QTTB icon

Tower Research Capital (TRC)’s Q32 Bio QTTB Stock Holding History

Tower Research Capital (TRC)’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Buy
1,871
+895
+92% +$4.25K ﹤0.01% 3811
2025
Q4 		$3.24K Sell
976
-5,506
-85% -$15.6K ﹤0.01% 4400
2025
Q3 		$12.8K Buy
6,482
+230
+4% +$442 ﹤0.01% 3745
2025
Q2 		$9.31K Buy
6,252
+3,075
+97% +$5.24K ﹤0.01% 3994
2025
Q1 		$5.24K Buy
3,177
+1,701
+115% +$4.58K ﹤0.01% 4139
2024
Q4 		$5.08K Buy
1,476
+1,284
+669% +$40.5K ﹤0.01% 4354
2024
Q3 		$8.57K Sell
192
-2,010
-91% -$73.9K ﹤0.01% 3953
2024
Q2 		$39.5K Buy
+2,202
New +$52.7K ﹤0.01% 3275
2023
Q4 		– Sell
-18
Closed -$371 – 6211
2023
Q3 		$371 Buy
+18
New +$367 ﹤0.01% 5585
2023
Q2 		– Sell
-133
Closed -$2K – 6407
2023
Q1 		$2K Sell
133
-864
-87% -$21.5K ﹤0.01% 5417
2022
Q4 		$23K Buy
997
+658
+194% +$17.5K ﹤0.01% 3016
2022
Q3 		$10K Sell
339
-48
-12% -$1.96K ﹤0.01% 4584
2022
Q2 		$14K Buy
387
+204
+111% +$6.96K ﹤0.01% 4174
2022
Q1 		$10K Sell
183
-1,291
-88% -$80.2K ﹤0.01% 4369
2021
Q4 		$96K Buy
1,474
+1,412
+2,277% +$137K ﹤0.01% 2248
2021
Q3 		$8K Sell
62
-124
-67% -$15.8K ﹤0.01% 4577
2021
Q2 		$24K Buy
186
+1
+0.5% +$125 ﹤0.01% 3741
2021
Q1 		$32K Sell
185
-16
-8% -$3.37K ﹤0.01% 3527
2020
Q4 		$41K Sell
201
-1,331
-87% -$257K ﹤0.01% 3310
2020
Q3 		$296K Buy
1,532
+987
+181% +$221K ﹤0.01% 2204
2020
Q2 		$149K Buy
+545
New +$145K 0.01% 2079
2020
Q1 		– Sell
-184
Closed -$69K – 4037
2019
Q4 		$69K Buy
184
+147
+397% +$42.1K 0.01% 1144
2019
Q3 		$12K Buy
+37
New +$12.6K ﹤0.01% 2841
2019
Q2 		– Sell
-27
Closed -$14K – 4405
2019
Q1 		$14K Buy
+27
New +$12.1K ﹤0.01% 2489

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tower Research Capital (TRC)'s QTTB Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Q32 Bio (QTTB) stake by 92% in Q1 2026, buying an estimated $4.25K and bringing the position to 1,871 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #3811.

Tower Research Capital (TRC) first reported a position in QTTB in Q1 2019 and has held it in 24 quarters since. The position peaked at $296K in Q3 2020. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Tower Research Capital (TRC) held 1,871 shares of Q32 Bio worth $12K as of Q1 2026.
  • Tower Research Capital (TRC) bought 895 Q32 Bio shares in Q1 2026, an estimated $4.25K.
  • Q32 Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3811 holding.
  • Tower Research Capital (TRC) first reported a position in Q32 Bio in Q1 2019 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Q32 Bio position peaked at $296K in Q3 2020.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.